Drug Topics

AUGUST 7, 2024

Make every month a celebration of wellbeing at the pharmacy by leveraging disease awareness initiatives.

281

281

STAT

AUGUST 7, 2024

The nation’s largest health care company pressed thousands of its clinicians to use a thinly tested medical device to screen people for artery disease, dramatically boosting payments from the federal government for years even though many of the patients were not sick, a STAT investigation found. The result was a torrent of sometimes questionable diagnoses of peripheral artery disease.

Insurance 145

Insurance 145

Drug Topics

AUGUST 7, 2024

In a recent conversation with Drug Topics on Over the Counter, Mark Garofoli discusses why men avoid seeking medical help for pain, as well as potential solutions.

253

253

Pharmacy Times

AUGUST 7, 2024

Significant commonalities between type 2 diabetes and neurodegenerative disorders suggest that treatments effective for one condition may benefit the other.

145

145

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

Patient Care

Drug Topics

AUGUST 7, 2024

Mark Garofoli delves deeper into the challenges men face when it comes to acknowledging pain, underscoring the critical need to dismantle the surrounding stigma.

247

247

Pharmacy Times

AUGUST 7, 2024

Cholesterol-lowering agents, like statins, reduced the risk of major adverse cardiovascular events and cardiovascular disease in patients with HIV.

144

144

Pharmacy Times

AUGUST 7, 2024

This breakthrough can be significant in the development for a vaccine and other preventative measures to protect individuals from leishmaniasis.

Vaccines 143

Vaccines 143

STAT

AUGUST 7, 2024

As I hurried to an important meeting about my Ph.D. dissertation one day in 2015, I slipped and fell on Iowa’s formidable winter ice. I quickly jumped up to prevent anyone from seeing me on the ground and got into my car. The immediate, excruciating pain told me that something really bad had happened. As I drove to my meeting in tears, I called my sister.

134

134

Pharmacy Times

AUGUST 7, 2024

Two pediatric oncology pharmacists emphasize pharmacists personalize supportive care, educate patients and their caregivers, advocate for patients, and collaborate with other health care workers.

132

132

STAT

AUGUST 7, 2024

LONDON — Patients in England with a rare blood disorder will now be able to receive the world’s first CRISPR-based medicine, after drugmaker Vertex Pharmaceuticals and U.K. health officials struck a reimbursement deal for the pricey treatment. The National Institute for Health and Care Excellence, the U.K.’s cost-effectiveness watchdog, said early Thursday that it was recommending the treatment, called Casgevy, for certain patients with beta thalassemia, a condition that oth

133

133

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

PharmaVoice

AUGUST 7, 2024

Arialys Therapeutics is developing a preclinical treatment for a rare autoimmune encephalitis that mimics psychosis.

130

130

STAT

AUGUST 7, 2024

Purdue Pharma, the company best known for fueling the opioid crisis by misleadingly marketing the infamous painkiller OxyContin, received approval on Wednesday for a new auto-injector device used to reverse opioid overdoses.  The announcement represents the latest in a string of recent approvals for products that use nalmefene, essentially a more powerful version of its better-known chemical cousin, naloxone.

FDA 127

FDA 127

PharmaVoice

AUGUST 7, 2024

The biotech boasts some Big Pharma backers that drove a $100 million fundraising effort in July to take its depression drug into a mid-stage study.

130

130

pharmaphorum

AUGUST 7, 2024

Explore the innovative applications of mRNA technologies beyond COVID-19 vaccines. Learn about the potential and future developments in this groundbreaking field.

Vaccines 126

Vaccines 126

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

FDA

STAT

AUGUST 7, 2024

Novo Nordisk is pulling its regulatory submissions to expand the use of its obesity drug Wegovy for a common type of heart failure, saying that waiting for more data on cardiovascular outcomes could bolster its case. Trials of Wegovy in the condition, heart failure with preserved ejection fraction (or HFpEF), have primarily looked at the drug’s effects on symptoms and physical function.

Hospitals 124

Hospitals Labelling 124

Pharmacy Times

AUGUST 7, 2024

Following a healthy, vitamin rich diet with less sugar was connected to a lower epigenetic age.

122

122

STAT

AUGUST 7, 2024

The Centers for Medicare and Medicaid Services has finalized its rule easing reimbursement for medical device makers. Called Transitional Coverage for Emerging Technologies, the program gives device makers with products deemed “breakthrough” technology by the Food and Drug Administration a quicker way to secure Medicare coverage. The agency first introduced the rule last June.

FDA 122

FDA 122

Fierce Healthcare

AUGUST 7, 2024

Centene is exiting six states through its WellCare Medicare Advantage subsidiary next year, investment bank Stephens has revealed. | WellCare is leaving six states next year, impacting more than 37,000 Centene members across the country.

121

121

Advertisement

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

Pharmacy Management Software

Pharmacy Times

AUGUST 7, 2024

Carbidopa and levodopa extended-release capsules are a novel, oral formulation that combines immediate-release granules and extended-release pellets.

FDA 120

FDA 120

STAT

AUGUST 7, 2024

The U.S. Food and Drug Administration has scolded Bristol Myers Squibb for making false and misleading claims about a lung cancer treatment on a website aimed at physicians. In an Aug. 1 letter , the agency admonished the company for touting the benefits of its Krazati medication by referencing efficacy data that did not support statements on the website designed for health care providers.

FDA 120

FDA 120

pharmaphorum

AUGUST 7, 2024

BioMarin Pharma has decided not to divest its haemophilia A gene therapy Roctavian but is reining back its ambitions for the business, for now

119

119

STAT

AUGUST 7, 2024

LONDON — An underwhelming earnings report and ongoing questions about increasing competition in the booming obesity medicine field sent Novo Nordisk’s shares down early Wednesday, as the company sought to project its ability to reach more patients by increasing the supplies of its medicines.   Novo shares were down about 5% after the company lowered its operating profit guidance to 20% to 28%, down from the 22% to 30% it forecasted in its last earnings report.

116

116

pharmaphorum

AUGUST 7, 2024

Explore how artificial intelligence and machine learning are revolutionising the medical devices sector. Learn about the innovative technologies and how companies are navigating evolving regulations in this rapidly advancing field.

114

114

STAT

AUGUST 7, 2024

CVS Health continued to pay out more than it expected for the medical claims of its Medicare Advantage enrollees in the second quarter, forcing the company to lower its estimates for this year’s profits for the second straight quarter. Those higher medical costs led CVS chief executive Karen Lynch to remove Brian Kane , the president of Aetna, the subsidiary that operates all health insurance plans.

Insurance 112

Insurance 112

Pharmacy Times

AUGUST 7, 2024

The ADA Clinical Practice Recommendations added sleep assessment for precision medicine in type 2 diabetes, supporting the wealth of information surrounding the association.

111

111

STAT

AUGUST 7, 2024

The polarized debate over drug pricing has generated cartoonish, sometimes colorful caricatures of the biopharmaceutical industry and its leaders. Critics of the industry have portrayed pharmaceutical leaders as ruthless, rapacious leaders who gouge patients to gratify greedy shareholders. While one might expect industry trade organizations to defend their leaders, their responses have sometimes portrayed leaders as powerless proxies of their shareholders whose product portfolios and profits wou

112

112

Pharmafile

AUGUST 7, 2024

Genomic medicine company Sangamo Therapeutics and Genentech have entered into a licensing agreement to develop intravenously administered genomic medicines to treat neurodegenerative diseases. Sangamo is expected to receive $50m in near-term upfront license fees and milestone payments after granting Genentech exclusive licensing for its proprietary zinc finger repressors – that are directed to the tau […] The post Sangamo Therapeutics and Genentech team up to develop genomic medicines for

111

111

Pharmacy Times

AUGUST 7, 2024

This marks the first FDA-approved systemic therapy for patients with grade 2 astrocytoma or oligodendroglioma with a susceptible isocitrate dehydrogenase-1 (IHD1) or IDH2 mutation.

FDA 111

FDA 111

pharmaphorum

AUGUST 7, 2024

Weaker sales of obesity drug Wegovy cause a dip in Novo Nordisk's share price, but CEO says volume growth is strong and will accelerate in second half

111

111

Fierce Healthcare

AUGUST 7, 2024

Coming off a recent debt financing round, NeueHealth reported a net loss but small adjusted EBITDA profit during its second-quarter earnings results. | NeueHealth's second-quarter results were without significant surprises, though the company noted a moderate increase in membership.

110

110

STAT

AUGUST 7, 2024

Hello, everyone, and how are you today? We are doing just fine, thank you, especially since the middle of the week is upon us. After all, we have made it this far, so we are determined to hang on for another couple of days. And why not? The alternatives — at least those we can identify — are not so appetizing. And what better way to make the time fly than to keep busy.

107

107

Fierce Healthcare

AUGUST 7, 2024

As it seeks to boost its financial fortunes, CVS Health has "identified a multiyear opportunity" to generate as much as $2 billion in savings, CEO Karen Lynch told investors Wednesday. | As it seeks to boost its financial fortunes, CVS Health has "identified a multiyear opportunity" to generate as much as $2 billion in savings, CEO Karen Lynch told investors Wednesday.

110

110

Fierce Pharma

AUGUST 7, 2024

The first horse carrying Novartis’ immunoglobulin A nephropathy (IgAN) troika has crossed the FDA finish line. | The first horse carrying Novartis’ immunoglobulin A nephropathy (IgAN) troika has crossed the FDA finish line.

FDA 106

FDA 106